Protocol Ledger

NCT04639310 · Phase III · TERMINATED

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Interventional Phase III clinical trial protocol NCT04639310 sponsored by Xenon Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-29 Enrollment: 8 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04639310
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)8 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04639310
Protocol FieldVerified Registry Value
NCT IdentifierNCT04639310
Consolidated Lead SponsorXenon Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment8 participants (ACTUAL)
Registered Start Date2021-03-29
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI